会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • THERAPEUTIC APPLICATION OF KAZAL-TYPE SERINE PROTEASE INHIBITORS
    • 卡氏型丝氨酸蛋白酶抑制剂的治疗应用
    • WO2008098720A1
    • 2008-08-21
    • PCT/EP2008/001009
    • 2008-02-11
    • CSL BEHRING GMBHSCHULTE, StefanKRONTHALER, UlrichSCHMIDBAUER, StefanWEIMER, ThomasHOFMANN, Kay
    • SCHULTE, StefanKRONTHALER, UlrichSCHMIDBAUER, StefanWEIMER, ThomasHOFMANN, Kay
    • A61K38/57A61P7/02C07K14/81
    • C07K14/8135A61K38/00A61K47/64A61K47/643
    • The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type serine protease inhibitor lnfestin or domains thereof or modified Kazal-type serine protease inhibitors based on lnfestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. In particular the present invention relates to the use of said Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors, in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i. e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.
    • 本发明的主题在最一般的方面是基于伊斯匹林同系物的Kazal型丝氨酸蛋白酶抑制剂腹膜内酯或其结构域或修饰的Kazal型丝氨酸蛋白酶抑制剂的治疗应用,其阻止形成和/或稳定化 通过干扰参与所谓的内在凝血途径的激活的蛋白质的三维动脉或静脉血栓。 特别地,本发明涉及所述Kazal型丝氨酸蛋白酶抑制剂或其片段或修饰的Kazal型丝氨酸蛋白酶抑制剂在治疗或预防与动脉血栓形成相关的病症或障碍中的用途, 即 中风或心肌梗塞,炎症,补体激活,纤维蛋白溶解,血管生成和/或与病理激肽形成相关的疾病,例如低渗休克,包括遗传性血管性水肿,细菌感染,关节炎,胰腺炎或关节痛风的水肿,弥散性内皮内凝血(DIC)和 败血症。